Etomidate (hydrochloride)

Modify Date: 2024-01-03 16:57:50

Etomidate (hydrochloride) structure	Common Name	Etomidate (hydrochloride)
	CAS Number	53188-20-8	Molecular Weight	280.75000
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₄H₁₇ClN₂O₂	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Etomidate (hydrochloride)

Etomidate Hcl(R16659 Hcl) is a GABAA receptors agonist, which is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia.Target: GABA ReceptorEtomidate is a potent inhibitor of the adrenal response to surgery. The absence of clinical consequences associated with the blunted response suggests that a major increase in adrenal hormone production may not be necessary during surgery [1]. Etomidate is an intravenous induction agent that is associated with hemodynamic stability during intubation. The agent is therefore attractive for use in critically ill patients who have a high risk of hemodynamic instability during this procedure [2]. Etomidate use was not associated with all cause 28-day mortality or hospital mortality but was associated with significantly higher ICU mortality (91% vs. 64% for etomidate and controls groups, respectively; p = 0.02). Etomidate patients who received subsequent doses of hydrocortisone required lower doses of vasopressors and had more vasopressor-free days but no improvement in mortality [3].Clinical indications: FDA Approved Date: 1983Toxicity: Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.

Name	ethyl 3-[(1S)-1-phenylethyl]imidazole-4-carboxylate,hydrochloride
Synonym	More Synonyms

Description	Etomidate Hcl(R16659 Hcl) is a GABAA receptors agonist, which is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia.Target: GABA ReceptorEtomidate is a potent inhibitor of the adrenal response to surgery. The absence of clinical consequences associated with the blunted response suggests that a major increase in adrenal hormone production may not be necessary during surgery [1]. Etomidate is an intravenous induction agent that is associated with hemodynamic stability during intubation. The agent is therefore attractive for use in critically ill patients who have a high risk of hemodynamic instability during this procedure [2]. Etomidate use was not associated with all cause 28-day mortality or hospital mortality but was associated with significantly higher ICU mortality (91% vs. 64% for etomidate and controls groups, respectively; p = 0.02). Etomidate patients who received subsequent doses of hydrocortisone required lower doses of vasopressors and had more vasopressor-free days but no improvement in mortality [3].Clinical indications: FDA Approved Date: 1983Toxicity: Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor Signaling Pathways >> Neuronal Signaling >> GABA Receptor Research Areas >> Neurological Disease
References	[1]. Mehta, M.P., et al., Etomidate anesthesia inhibits the cortisol response to surgical stress. Acta Anaesthesiol Scand, 1985. 29(5): p. 486-9. [2]. Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here? Crit Care, 2012. 16(6): p. 189. [3]. Cherfan, A.J., et al., Etomidate and mortality in cirrhotic patients with septic shock. BMC Clin Pharmacol, 2011. 11: p. 22.

Description

Related Catalog

Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor

Signaling Pathways >> Neuronal Signaling >> GABA Receptor

Research Areas >> Neurological Disease

References

[1]. Mehta, M.P., et al., Etomidate anesthesia inhibits the cortisol response to surgical stress. Acta Anaesthesiol Scand, 1985. 29(5): p. 486-9.

[2]. Griesdale, D.E., Etomidate for intubation of patients who have sepsis or septic shock - where do we go from here? Crit Care, 2012. 16(6): p. 189.

[3]. Cherfan, A.J., et al., Etomidate and mortality in cirrhotic patients with septic shock. BMC Clin Pharmacol, 2011. 11: p. 22.